C4T Securities Corporation

Call
Website
490 Arsenal St Ste 120
Watertown, MA 02472
+1 (617) 231-0700
http://c4therapeutics.com

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in targeted protein degradation. Their innovative approach, known as Targeted Protein Degradation (TPD), aims to develop a new generation of medicines for treating various diseases. Through their TORPEDO platform and focus on target selection, C4 Therapeutics is dedicated to transforming lives by degrading disease-causing proteins.

With a strong leadership team, board of directors, and scientific advisory board, C4 Therapeutics is committed to advancing their pipeline of therapies, including CFT7455, CFT1946, and CFT8919. They also collaborate with industry partners such as Roche, Biogen, Betta Merck, and others to further their research and development efforts. At C4 Therapeutics, their values, people, and dedication to scientific progress drive their mission to revolutionize the treatment of diseases through targeted protein degradation.

Generated from the website

Also at this address

Own this business?
See a problem?

You might also like

Drugs acting on the respiratory system, Blood derivatives, Surgical instruments and apparatus

Relay Therapeutics

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.
Drugs acting on the respiratory system, Vitamin, nutrient, and hematinic preparations for human use

Akebia Therapeutics, Inc

Akashi Therapeutics, based in Cambridge, is a global biopharmaceutical company with a focus on developing innovative therapies for individuals affected by rare disorders. The company's mission is to create life-changing treatments that address the unmet medical needs of those living with rare diseases, aiming to improve the quality of life for patients worldwide. Generated from their website's infomation
Drugs acting on the respiratory system, Blood derivatives, Surgical instruments and apparatus

Biogen US Corp

Headquartered in Cambridge, Mass., Biogen Idec specializes in the field of biotechnology. Its core capabilities include drug discovery, research and development. The company s focus is the development of products related to oncology, neurology and immunology. Among the company s products are treatments for B-cell, non-Hodgkin s lymphomas; a treatment for relapsing forms of multiple sclerosis; and a treatment for psoriasis and psoriatic arthritis. In addition, the company has several licensed and dedicated bulk-manufacturing facilities engaged in protein manufacturing. James C. Mullen has been the chief executive officer of Biogen Indec for more than two years. He has been with the drug and biotechnology company for over 17 years. Mullen earned a BS degree from Rensselaer Polytech, and a MBA from Villanova. The company maintains research centers in Cambridge, Mass., and San Diego. Biogen Idec has additional offices in Canada, Australia, Japan and Europe, including international headquarters in Zug, Switzerland. The company currently employs approximately 3,400 people worldwide.
United States›Massachusetts›Watertown›C4T Securities Corporation

Partial Data by Infogroup (c) 2025. All rights reserved.